Medifast, Inc. — 2014 Form 10-K
Reporting period: Fiscal year ended December 31, 2014. The filing was signed in March 2015. Medifast sells weight-management and nutrition products through direct sales, its Take Shape For Life coach network, wholesale, and franchised centers.
Financial performance and liquidity
- FY 2014 revenue: $285.3 million, down 12% from $324.1 million in 2013. Take Shape For Life generated 72.5% of revenue; Medifast Direct 20.0%; franchised centers 5.4%; and wholesale 2.1%.
- Profitability: Gross profit was $209.2 million, with a 73.3% gross margin versus 74.2% in 2013. Operating income was $30.2 million, down 21%, and operating margin declined to 10.6% from 11.9%. Continuing-operations income was $21.0 million, down 23%; net income was $13.2 million, down 45%. Diluted EPS was $1.03, versus $1.73.
- Fourth quarter: Revenue was $62.3 million versus $70.3 million in Q4 2013. Income from continuing operations was $2.6 million; net loss was $3.4 million, compared with net income of $5.3 million a year earlier. Diluted EPS was a loss of $0.28 versus earnings of $0.39.
- Cash flow: Cash from operating activities was $25.5 million overall, including $27.3 million from continuing operations and $1.8 million used by discontinued operations. Investing activities used $2.5 million; financing activities used $34.9 million, principally reflecting $33.9 million of share repurchases.
- Liquidity and debt: Year-end cash and equivalents were $24.5 million, investment securities $28.2 million, working capital $55.0 million, and stockholders’ equity $80.5 million. Capital lease obligations totaled $474,000; the company reported no outstanding borrowings under its $5 million unsecured revolving credit line, which expires August 1, 2015. Cash declined from $36.4 million at year-end 2013.
Material changes versus 2013
- Take Shape For Life revenue fell 10% to $206.7 million, alongside fewer active Health Coaches (9,300 versus 10,500) and lower average monthly revenue per coach ($1,524 versus $1,605).
- Medifast Direct revenue fell 24% to $57.2 million. Management cited lower marketing efficiency and customer acquisition and reduced advertising spend to protect profitability.
- Wholesale revenue rose 30% to $6.0 million; franchised-center revenue was nearly flat at $15.4 million.
- Medifast sold 41 corporate weight-control centers to franchisees and closed 34 others. These corporate-center operations were reported as discontinued operations. Revenue from discontinued operations was $22.5 million; the after-tax loss was $7.8 million, including an $8.6 million pre-tax exit charge.
Outlook, commentary, risks, and unusual items
- Management expected a 2015 effective tax rate of approximately 33%–34%. The filing does not provide a clear revenue or earnings forecast.
- Management said future cash needs, if any, were expected to be funded from operating cash flow and financing activities, and expected to extend or replace the credit line at its August 2015 expiry.
- 2014 SG&A included $2.6 million of extraordinary legal expenses related to 13D filings and a $2.0 million accrual for a guaranteed franchise loan default. The company reported a $2.0 million accrued exposure on a guarantee covering a franchisee’s $1.0 million loan and $1.0 million line of credit; it expected to perform under the guarantee. A separate guaranteed loan had a $0.1 million outstanding balance as of March 10, 2015.
- Closed-center obligations included $6.5 million accrued at year-end, principally lease obligations, customer refunds, severance, and other closure costs. The filing also disclosed $3.8 million of future minimum sublease income associated with lease commitments, which had not reduced the stated minimum lease payments.
- Other material risks include demand and advertising effectiveness, Health Coach retention and conduct, product liability and adverse publicity, regulation of advertising and direct selling, supply-chain dependence, cybersecurity, competition, and international-market exposure.
- The company’s defamation and market-manipulation lawsuit sought $270 million; proceedings remained pending, and settlement discussions were ongoing. Medifast stated it did not believe its other incidental proceedings would materially affect results, financial position, or liquidity. Its 2012 FTC consent decree required changes to advertising substantiation practices; the company paid a $3.7 million penalty in 2012.
- The board adopted a stockholders’ rights plan in August 2014, with rights due to expire August 28, 2015 unless earlier exercised, redeemed, exchanged, or terminated. No common-stock dividends were declared in 2014 or 2013.
Important facts for investors to verify
- Whether the declines in core Take Shape For Life and Medifast Direct sales and active-coach counts continued after year-end.
- The final cash cost and recovery prospects for the defaulted franchise guarantee and the remaining guaranteed loan exposure.
- Whether closed-center leases are terminated or sublet as planned, and whether accrued exit costs adequately cover obligations.
- The terms and renewal or replacement status of the $5 million credit facility expiring in August 2015.
- Developments in the $270 million lawsuit, the 13D-related legal matters, and any resulting legal expense or governance changes.
- Cash generation, investment-security liquidity, and the effect of ongoing share repurchases on cash and equity.